Department of Applied Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India.
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6261-6. doi: 10.1016/j.bmcl.2012.07.098. Epub 2012 Aug 4.
Several options for treating Herpes Simplex Virus type 1 and type 2 are available. However, non-specific inhibition and drug resistance warrants the discovery of new anti-herpetic compounds with better therapeutic profile or different mode of action. The non-nucleoside inhibitors of HSV DNA polymerase target the site that is less important for the binding of a natural nucleoside or nucleoside inhibitors. In the present study, we have explored the possibility to find a new lead molecule based on α-pyrone analogs as non-nucleoside inhibitors using structure based modeling approach. The designed molecules were synthesized and evaluated for anti-HSV activity using MTT assay. The compound 5h with EC(50) 7.4μg/ml and CC(50) 52.5μg/ml was moderately active against HSV when compared to acyclovir. A plaque reduction assay was also carried out and results reveal that 5h is more effective against HSV-1 with better selective index of 12.8 than against HSV-2 (SI=3.6). The synthesized compounds were also evaluated for anti-HIV activity, but none were active.
有几种治疗单纯疱疹病毒 1 型和 2 型的方法。然而,非特异性抑制和药物耐药性需要发现具有更好治疗效果或不同作用模式的新型抗疱疹化合物。HSV DNA 聚合酶的非核苷抑制剂针对的是与天然核苷或核苷抑制剂结合不太重要的部位。在本研究中,我们使用基于结构的建模方法探索了基于α-吡喃酮类似物作为非核苷抑制剂寻找新先导分子的可能性。设计的分子被合成并通过 MTT 测定法评估其抗 HSV 活性。与阿昔洛韦相比,具有 EC(50) 7.4μg/ml 和 CC(50) 52.5μg/ml 的化合物 5h 对 HSV 具有中等活性。还进行了蚀斑减少测定,结果表明 5h 对 HSV-1 更有效,选择性指数为 12.8,优于 HSV-2(SI=3.6)。还评估了合成化合物的抗 HIV 活性,但均无活性。